Page 1

AMGEN News Release ● AMGEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS THOUSAND OAKS , Calif . ( November 2 , 2021 ) - Amgen ( NASDAQ : AMGN ) today announced financial results for the third quarter of 2021. Key results include : O Ⓡ Total revenues increased 4 % to $ 6.7 billion in comparison to the third quarter of 2020 , driven by higher unit demand , partially offset by lower net selling prices . One Amgen Center Drive Thousand Oaks , CA 91320-1799 Telephone 805-447-1000 www.amgen.com O GAAP earnings per share ( EPS ) decreased 3 % to $ 3.31 driven by a $ 400 million licensing - related expense from our collaboration with Kyowa Kirin Co. , Ltd. ( Kyowa Kirin ) , partially offset by increased revenues . O Product sales increased 4 % globally , driven by double - digit volume growth across a number of our products , including Prolia® ( denosumab ) , EVENITY® ( romosozumab - aqqg ) , RepathaⓇ ( evolocumab ) and MVASIⓇ ( bevacizumab - awwb ) . GAAP operating income decreased 3 % to $ 2.4 billion , and GAAP operating margin decreased 2.6 percentage points to 37.6 % . Non - GAAP EPS increased 11 % to $ 4.67 driven by increased revenues and the impact of fewer weighted average shares outstanding . Total non - GAAP operating expenses increased less than 1 % . Non - GAAP operating income increased 8 % to $ 3.5 billion , and non - GAAP operating margin increased 2.5 percentage points to 54.6 % . The Company generated $ 2.2 billion of free cash flow in the third quarter versus $ 3.2 billion in the third quarter of 2020 , driven by higher collections in the third quarter of 2020 from customers who had been granted extended payment terms due to COVID - 19 . This increase was partially offset by the timing of tax payments in the third quarter of 2020 . 2021 total revenues guidance of $ 25.8- $ 26.2 billion ; EPS guidance of $ 9.55- $ 10.21 on a GAAP basis and $ 16.50- $ 17.10 on a non - GAAP basis . " Our newest proc LUMAKRASⓇ , a first - in - class lung cancer treatment , is off to a strong start and our robust pipeline of potential new medicines across all stages of development sets us up well to drive growth over the long term , " said Robert A. Bradway , chairman and chief executive officer . " We achieved solid growth in the quarter as our medicines reached an increasing number of patients around the world . "